Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Printable Handouts
Navigable Slide Index
- Introduction
- Disclaimer
- Overview
- Part 1
- What are ATMPs?
- Different from traditional medicines
- EMA’s evaluation: Entry route of ATMPs to the EU market
- EMA issues opinion and EC issues decision to grant marketing authorisation
- Approved ATMPs 2009-2021
- ATMPs: Challenges in their lifecycle
- Innovative medicines: Challenges for regulators
- EMA tools to support drug development
- Preparing for a sound ATMP development: EMA support through scientific advice (SA)
- Critical aspects to be addressed during development
- Increase in SA for ATMPs over period 2009–2020
- Positive impact of SA adherence on MAA procedure and outcome
- EMA scientific advice in parallel with FDA
- Qualification of novel methodologies/biomarkers/registries
- Advice on RMPs, PASS & PAES
- Need for additional data sources in pre- and post-approval phase
- Further information
- Part 1 summary
- Part 2
- Regulatory Scientific Strategy to 2025 - highlights for ATMPs
- Current gaps and bridges
- Early bridges - academia liaison: The hub linking the agency and academia
- Early bridges - PRIME scheme: Goal and Scope
- Early bridges - eligibility to PRIME scheme: Based on accelerated assessment criteria
- Early bridges - The quality PRIME toolbox
- Early bridges - complex clinical trials
- Late bridges - New EU framework for cooperation on HTA update
- Scientific advice in parallel with HTA bodies
- Other challenges - the global picture
- Other challenges - International harmonization versus convergence EU July 2021
- Other challenges - COVID: Lessons learnt
- Other challenges - Unproven cell-based therapies
- What developers can do
- ATMP overview
- Thank you for your attention
Topics Covered
- Introduction to ATMPs
- Route of approval in Europe
- Approved ATMPs 2009-2021
- ATMPs: Challenges for regulators
- Challenges to be addressed during development
- What support tools developers can use
- Future challenges of ATMPs
- Potential bridges and solutions
Links
Categories:
External Links
- Advanced therapy medicinal products: Overview
- EMA Regulatory science to 2025
- PRIME: a two-year overview
- PRIME: priority medicines
- Draft toolbox guidance on scientific elements and
- EMA address (visits and deliveries)
- EMA send us a question
- Regulation 1394/2007 on ATMPs
- Directive 2001/83/EC
- Regulation (EC) 726/2004
- Directive 2009/120/EC
Talk Citation
Hidalgo-Simon, A. (2021, December 13). Regulation of ATMPs in Europe: present and future [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/YEPX8994.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Ana Hidalgo-Simon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Ana Hidalgo-Simon,
and I work for the European Medicines Agency (EMA).
In this talk today,
I'm going to be talking about the regulation of ATMPs in Europe.
The European Medicines Agency is
the coordination hub for the regulation of medicines in Europe.
We do have more than one per country in Europe, that is national competence authorities,
but for these complex therapies, we do the coordination
and all the regulatory life from the central hub which is the EMA.
0:39
I do not have any conflict of interest.
0:44
This talk is divided into two parts.
In Part 1, I'm going to be describing what we understand about ATMPs,
what they are, and how they are regulated.
Also a description of the available tools for developers and users.
In Part 2, I will be talking about the future, going over the challenges
going over the challenges that we have at the moment
and the potential bridges that we are putting in to address those challenges.
1:13
We move now onto Part 1.
How do we classify and describe advanced therapies in Europe?
1:24
ATMPs are classified in Europe in three large brackets,
but you will have to be a bit careful in assuming that these definitions will apply everywhere
because it doesn't at the moment.
You will find that what is classified as gene therapy in Europe and in the FDA has a large overlap,
but it's not exactly the same.
The therapies in these three brackets:
gene therapies, somatic cell therapies and tissue-engineered products,
are all considered ATMPs and they are regulated as medicines in the EU.
In contrast to that,
you have transplants, transfusions,
or the movement of cells that are non substantially
manipulated into a homologous position in the body,
and those are not regulated as medicines.
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)